Mfn2 ubiquitination by PINK1/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy

  1. Gian-Luca McLelland
  2. Thomas Goiran
  3. Wei Yi
  4. Geneviève Dorval
  5. Carol X Chen
  6. Nadine D Lauinger
  7. Andrea I Krahn
  8. Sepideh Valimehr
  9. Aleksandar Rakovic
  10. Isabelle Rouiller
  11. Thomas M Durcan
  12. Jean-François Trempe
  13. Edward A Fon  Is a corresponding author
  1. Montreal Neurological Institute and Hospital, McGill University, Canada
  2. McGill University, Canada
  3. University of Lübeck, Germany

Abstract

Despite their importance as signaling hubs, the function of mitochondria-ER contact sites in mitochondrial quality control pathways remains unexplored. Here we describe a mechanism by which Mfn2, a mitochondria-ER tether, gates the autophagic turnover of mitochondria by PINK1 and parkin. Mitochondria-ER appositions are destroyed during mitophagy, and reducing mitochondria-ER contacts increases the rate of mitochondrial degradation. Mechanistically, parkin/PINK1 catalyze a rapid burst of Mfn2 phosphoubiquitination to trigger p97-dependent disassembly of Mfn2 complexes from the outer mitochondrial membrane, dissociating mitochondria from the ER. We additionally demonstrate that a major portion of the facilitatory effect of p97 on mitophagy is epistatic to Mfn2 and promotes the availability of other parkin substrates such as VDAC1. Finally, we reconstitute the action of these factors on Mfn2 and VDAC1 ubiquitination in a cell-free assay. We show that mitochondria-ER tethering suppresses mitophagy and describe a parkin-/PINK1-dependent mechanism that regulates the destruction of mitochondria-ER contact sites.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for all Figures.

Article and author information

Author details

  1. Gian-Luca McLelland

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  2. Thomas Goiran

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  3. Wei Yi

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  4. Geneviève Dorval

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  5. Carol X Chen

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  6. Nadine D Lauinger

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  7. Andrea I Krahn

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  8. Sepideh Valimehr

    Department of Anatomy and Cell Biology, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  9. Aleksandar Rakovic

    Institute of Neurogenetics, University of Lübeck, Lübeck, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Isabelle Rouiller

    Department of Anatomy and Cell Biology, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  11. Thomas M Durcan

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  12. Jean-François Trempe

    Department of Pharmacology and Therapeutics, McGill University, Montréal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  13. Edward A Fon

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    For correspondence
    ted.fon@mcgill.ca
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5520-6239

Funding

Canadian Institutes of Health Research (Canada Graduate Scholarship)

  • Gian-Luca McLelland

Canadian Institutes of Health Research (Foundation Grant)

  • Edward A Fon

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2018, McLelland et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 9,767
    views
  • 1,995
    downloads
  • 280
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Gian-Luca McLelland
  2. Thomas Goiran
  3. Wei Yi
  4. Geneviève Dorval
  5. Carol X Chen
  6. Nadine D Lauinger
  7. Andrea I Krahn
  8. Sepideh Valimehr
  9. Aleksandar Rakovic
  10. Isabelle Rouiller
  11. Thomas M Durcan
  12. Jean-François Trempe
  13. Edward A Fon
(2018)
Mfn2 ubiquitination by PINK1/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy
eLife 7:e32866.
https://doi.org/10.7554/eLife.32866

Share this article

https://doi.org/10.7554/eLife.32866

Further reading

    1. Cell Biology
    2. Immunology and Inflammation
    Armando Montoya-Garcia, Idaira M Guerrero-Fonseca ... Michael Schnoor
    Research Article

    Arpin was discovered as an inhibitor of the Arp2/3 complex localized at the lamellipodial tip of fibroblasts, where it regulated migration steering. Recently, we showed that arpin stabilizes the epithelial barrier in an Arp2/3-dependent manner. However, the expression and functions of arpin in endothelial cells (EC) have not yet been described. Arpin mRNA and protein are expressed in EC and downregulated by pro-inflammatory cytokines. Arpin depletion in Human Umbilical Vein Endothelial Cells causes the formation of actomyosin stress fibers leading to increased permeability in an Arp2/3-independent manner. Instead, inhibitors of ROCK1 and ZIPK, kinases involved in the generation of stress fibers, normalize the loss-of-arpin effects on actin filaments and permeability. Arpin-deficient mice are viable but show a characteristic vascular phenotype in the lung including edema, microhemorrhage, and vascular congestion, increased F-actin levels, and vascular permeability. Our data show that, apart from being an Arp2/3 inhibitor, arpin is also a regulator of actomyosin contractility and endothelial barrier integrity.

    1. Cell Biology
    Parijat Biswas, Priyanka Roy ... Deepak Kumar Sinha
    Research Article

    The excessive cosolute densities in the intracellular fluid create a physicochemical condition called macromolecular crowding (MMC). Intracellular MMC entropically maintains the biochemical thermodynamic equilibria by favouring associative reactions while hindering transport processes. Rapid cell volume shrinkage during extracellular hypertonicity elevates the MMC and disrupts the equilibria, potentially ushering cell death. Consequently, cells actively counter the hypertonic stress through regulatory volume increase (RVI) and restore the MMC homeostasis. Here, we establish fluorescence anisotropy of EGFP as a reliable tool for studying cellular MMC and explore the spatiotemporal dynamics of MMC during cell volume instabilities under multiple conditions. Our studies reveal that the actin cytoskeleton enforces spatially varying MMC levels inside adhered cells. Within cell populations, MMC is uncorrelated with nuclear DNA content but anti-correlated with the cell spread area. Although different cell lines have statistically similar MMC distributions, their responses to extracellular hypertonicity vary. The intensity of the extracellular hypertonicity determines a cell's ability for RVI, which correlates with Nuclear Factor Kappa Beta (NFkB) activation. Pharmacological inhibition and knockdown experiments reveal that Tumour Necrosis Factor Receptor 1 (TNFR1) initiates the hypertonicity induced NFkB signalling and RVI. At severe hypertonicities, the elevated MMC amplifies cytoplasmic microviscosity and hinders Receptor Interacting Protein Kinase 1 (RIPK1) recruitment at the TNFR1 complex, incapacitating the TNFR1-NFkB signalling and consequently, RVI. Together, our studies unveil the involvement of TNFR1-NFkB signalling in modulating RVI and demonstrate the pivotal role of MMC in determining cellular osmoadaptability.